MX2020013669A - Formulaciones para vectores adenovirales de simio que tienen estabilidad mejorada. - Google Patents

Formulaciones para vectores adenovirales de simio que tienen estabilidad mejorada.

Info

Publication number
MX2020013669A
MX2020013669A MX2020013669A MX2020013669A MX2020013669A MX 2020013669 A MX2020013669 A MX 2020013669A MX 2020013669 A MX2020013669 A MX 2020013669A MX 2020013669 A MX2020013669 A MX 2020013669A MX 2020013669 A MX2020013669 A MX 2020013669A
Authority
MX
Mexico
Prior art keywords
formulations
adenoviral vectors
enhanced stability
simian adenoviral
simian
Prior art date
Application number
MX2020013669A
Other languages
English (en)
Inventor
Frédéric Mathot
Mathieu Vasselle
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of MX2020013669A publication Critical patent/MX2020013669A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a formulaciones líquidas de adenovirus de simio y métodos para obtener las formulaciones. Las formulaciones comprenden un azúcar amorfo, succinato de Vitamina E y albúmina de suero humano recombinante en una solución amortiguada.
MX2020013669A 2018-06-26 2019-06-25 Formulaciones para vectores adenovirales de simio que tienen estabilidad mejorada. MX2020013669A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18179977.6A EP3587581A1 (en) 2018-06-26 2018-06-26 Formulations for simian adenoviral vectors having enhanced storage stability
PCT/IB2019/055347 WO2020003126A1 (en) 2018-06-26 2019-06-25 Formulations for simian adenoviral vectors having enhanced stability

Publications (1)

Publication Number Publication Date
MX2020013669A true MX2020013669A (es) 2021-03-02

Family

ID=62837592

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013669A MX2020013669A (es) 2018-06-26 2019-06-25 Formulaciones para vectores adenovirales de simio que tienen estabilidad mejorada.

Country Status (8)

Country Link
US (1) US20210207171A1 (es)
EP (2) EP3587581A1 (es)
JP (1) JP7279086B2 (es)
CN (1) CN112469831A (es)
BR (1) BR112020025620A2 (es)
CA (1) CA3104601A1 (es)
MX (1) MX2020013669A (es)
WO (1) WO2020003126A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
JP2022536137A (ja) * 2019-06-11 2022-08-12 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 粘膜ワクチン製剤
PE20221182A1 (es) 2019-11-18 2022-08-05 Janssen Biotech Inc Vacunas basadas en calr y jak2 mutantes y sus usos

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU228327B1 (en) 2001-06-22 2013-03-28 Wistar Inst Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein
ATE449105T1 (de) 2004-01-23 2009-12-15 Angeletti P Ist Richerche Bio Impfstoffträger für schimpansen-adenovirus
SG172935A1 (en) 2009-02-02 2011-08-29 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
WO2011103114A1 (en) * 2010-02-17 2011-08-25 Hememics Biotechnologies, Inc. Preservation solutions for biologics and methods related thereto
EP2764014B1 (en) 2011-10-05 2022-02-09 GenVec, Inc. Adenoviral vectors and methods of use
IN2014DN03005A (es) 2011-10-05 2015-05-08 Genvec Inc
US9629906B2 (en) 2011-10-05 2017-04-25 Genvec, Inc. Affenadenovirus (gorilla) or adenoviral vectors and methods of use
CN108025058B (zh) 2015-06-12 2022-12-16 葛兰素史密丝克莱恩生物有限公司 腺病毒多核苷酸和多肽
GB201513010D0 (en) 2015-07-23 2015-09-09 Glaxosmithkline Biolog Sa Novel formulation
GB201701239D0 (en) * 2017-01-25 2017-03-08 Glaxosmithkline Biologicals Sa Novel formulation
KR102582561B1 (ko) 2017-07-05 2023-09-26 노우스콤 아게 비인간 대형 유인원 아데노바이러스 핵산-서열 및 아미노산-서열, 이를 포함하는 벡터 및 그의 용도

Also Published As

Publication number Publication date
JP2021529178A (ja) 2021-10-28
EP3814511A1 (en) 2021-05-05
JP7279086B2 (ja) 2023-05-22
US20210207171A1 (en) 2021-07-08
CN112469831A (zh) 2021-03-09
EP3587581A1 (en) 2020-01-01
WO2020003126A1 (en) 2020-01-02
CA3104601A1 (en) 2020-01-02
BR112020025620A2 (pt) 2021-03-23

Similar Documents

Publication Publication Date Title
MX2020013669A (es) Formulaciones para vectores adenovirales de simio que tienen estabilidad mejorada.
PH12018500594A1 (en) Adeno-associated virus factor viii vectors, associated viral particles and therapeutic formulations comprising the same
MX2019008413A (es) Celulas pluripotentes inmunodiseñadas.
MY180831A (en) Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
CL2019000167A1 (es) Novedosas proteínas de la cápside del virus adenoasociado.
WO2018083087A3 (en) Binding proteins
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
MY202018A (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
MX2021003554A (es) Proteinas de union a dll3 y metodos de uso.
MX2018014228A (es) Proteina de union de albumina sérica de dominio unico.
BR112016006564A2 (pt) proteínas de ligação desmogleína 2 (dsg2) e usos das mesmas
MX2021005018A (es) Composicion farmaceutica de proteina de fusion del receptor tgf-?, y uso de la misma.
BR112019010275A2 (pt) adenovírus recombinante, composição, uso do adenovírus ou composição, método de induzir uma resposta imune em um paciente, e, adenovírus de símio não humano
PH12019502025A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
MX2019007554A (es) Proteínas de uníon al antígeno anti-neuropilina, y sus métodos de uso.
PH12018502403A1 (en) Hiv vaccine formulation
MX2020005170A (es) Formulaciones de proteinas de fusion vegfr-fc.
MX2023004595A (es) Proteinas de fusion interleucina-2-fc y metodos de uso.
EP3735458A4 (en) RECOMBINANT HUMAN SIALIDASES, SIALIDASE FUSION PROTEINS AND METHODS OF USE THEREOF
PH12019501108A1 (en) Anti-gitr anti-binding protein and methods of use thereof
MY193519A (en) Method for decreasing immunogenicity of protein and peptide
CU20210041A7 (es) Péptidos inmunogénicos con motivos de oxidorreductasa
TW201613631A (en) Ghrelin secretion promoter
CR20220249A (es) Derivados terapéuticos de interleucina-22
MX2017011732A (es) Proteínas de fusión que comprenden glicoproteínas de la superficie del virus alfa modificado y antígeno asociado al tumor y métodos de los mismos.